Stock Price Soars Over 90% This Year
Brain Surgery Medical Robot Receives FDA Approval
Institutions Lead Rebound with 48.6 Billion Won Net Purchases
Goyoung's stock price, which had halved last year, is rapidly rebounding this year. Expectations for the surgical robot, a new business being promoted, are reflected in the rising stock price. Domestic institutional investors have led the stock price increase by actively purchasing Goyoung shares.
According to the financial investment industry on the 24th, Goyoung's stock price has risen 93.2% since the beginning of this year. Considering that the KOSDAQ index rose 6.8% during the same period, the return on investment compared to the market is 86.4 percentage points (P). The market capitalization jumped to 1.076 trillion won. Although foreigners recorded a cumulative net sale of 80 billion won this month, domestic institutional investors and individuals have purchased 48.6 billion won and 30.7 billion won worth of shares respectively this year.
Goyoung is a manufacturer of three-dimensional (3D) inspection equipment. It develops 3D precision measurement inspection equipment for electronic products and semiconductor production. The equipment detects defects occurring during the printed circuit board (PCB) assembly process by measuring them in three dimensions. As a new business, it is developing a high-precision image-guided surgical robot based on its core competencies in 3D measurement and robotics.
Up to the third quarter of last year, it recorded cumulative sales of 151.8 billion won and operating profit of 6 billion won, down 9% and 59% respectively compared to the same period the previous year. Due to continued poor performance, the stock price fell about 50% throughout the year, dropping from 16,550 won at the end of 2023 to 8,110 won.
This year, the stock price rebounded and recovered to the level at the end of 2023. Earlier, Goyoung announced on the 20th that its brain surgery medical robot (Geniant Cranial) had received approval from the U.S. Food and Drug Administration (FDA).
Goyoung succeeded in independently developing a brain surgery medical robot by participating in a national project of the Ministry of Trade, Industry and Energy. Subsequently, major domestic hospitals have consecutively introduced it, using it in high-difficulty brain disease surgeries such as Parkinson's disease and epilepsy, gaining recognition for its precision and safety. By combining navigation and robotic systems, it has improved surgical success rates and accuracy. It reduces patients' pain and the risk of complications, improving prognosis and gaining attention in the field of brain surgery.
The brain surgery medical robot approved by the U.S. FDA is a global version of 'KYMERO' called 'Geniant Cranial.' It uses artificial intelligence (AI) learning functions to analyze medical images, optimize surgical routes, and predict and respond to various situations that may occur during surgery.
Lee Sangheon, a researcher at iM Securities, explained, "KYMERO has achieved more than 500 successful brain surgeries cumulatively, so the sales growth rate will accelerate year by year." He added, "It is expected to be approved in Japan in the first half of this year and more than five units are expected to be sold in Japan this year."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
